PGxOne™ Plus is a pharmacogenomics test that can help predict how a patient will respond to drug therapy based on individual genetic makeup.

- Genetic variants affect drug absorption, metabolism and activity. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing.
- Provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac and pain medications
- Cutting-edge Next Generation Sequencing (NGS) technology enables comprehensive coverage of ~200 genetic variants in 50 genes.
- Delivers medically actionable recommendations in an easy to interpret report.

### Selected Covered Drug Classes from Major Therapeutic Areas

**Cardiology**  
- ACE Inhibitors  
- Angiotensin II Receptor Blockers (ARBs)  
- Antianginal Agent  
- Antiarrhythmic Agent  
- Anticoagulant  
- Antiplatelet  
- Beta Blockers  
- Calcium Channel Blockers  
- Diuretics  
- Phosphodiesterase Inhibitors  
- Antilipemic Agent (statins)  
- Vasodilators

<table>
<thead>
<tr>
<th>Psychiatry</th>
<th>Pain Management</th>
</tr>
</thead>
</table>
| Aldehyde Dehydrogenase Inhibitors  
Antianxiety Agents  
Antidepressants  
Antimanic Agents  
Antipsychotics  
Benzodiazepines  
Tricyclic Antidepressants  
Cannabinoids  
SNRIs  
SSRIs  
Stimulants | Anesthetics  
Central α-2 Adrenergic Agonists  
Alpha2-Adrenergic Agonist  
NSAIDs  
Opioids  
Opioids Antagonists  
Serotonin Receptor Agonists  
Skeletal Muscle Relaxant |

**Infectious Diseases**  
- Antibiotics  
- Antimalarial Drugs  
- Antiviral Drugs  
- Protease Inhibitors

**Neurology**  
- Anticonvulsant Drugs  
- Barbiturates  
- COMT Inhibitors  
- Monoamine Depletors  
- Antimigraine Agent

**Oncology**  
- Taxane Derivative  
- Antimetabolite  
- Platinum Analog  
- Alkylating Agent  
- Anthracycline  
- Chemotherapy Modulating Agent  
- Urate-Oxidase  
- Estrogen Receptor Modulator  
- Kinase Inhibitor  
- Antiemetic Topoisomerase Inhibitors  
- Immunomodulators  
- Vinca Alkaloids

Associated drugs carry pharmacogenomics recommendations put forth by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and/or related pharmacogenomics publications.
*PGxOne™ Plus is the most comprehensive, commercially available pharmacogenomics test covering more genes than competitors.

**Target Genes and Select Therapeutic Areas**

PGxOne™ Plus provides comprehensive coverage for major therapeutic areas.